How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol

INTRODUCTION: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are oral antihyperglycemic agents for the treatment of people with type 2 diabetes (T2DM). Two recent cardiovascular outcome trials (CVOTs), the EMPA-REG OUTCOME trial and CANVAS Program, have demonstrated that SGLT2 inhibitors have ca...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Diabetes Ther
Autores principales: Hinton, William, Feher, Michael D., Munro, Neil, de Lusignan, Simon
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Healthcare 2019
Materias:
Study Protocol
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6531500/
https://ncbi.nlm.nih.gov/pubmed/31041781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-0620-8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares